Skip to contentC
Cryo Cell International Inc
C
CCELCryo Cell International Inc Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.54M$7.54Mderived−5.4% vs Q4 2019 Net Income$1.20M$1.20Mderived+42.0% vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cryo Cell International Inc · CIK 862692 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$2,180,120+26.8% Operating Cash Flowderived$2,976,725+164.7% Free Cash Flowderived$2,929,159+202.1% Margins · derivedOperating margin28.9%+7.3 pt vs Q4 2019
Net margin15.9%+5.3 pt vs Q4 2019
ended Nov 30, 2020 · filed Mar 1, 2021 · 91 d after period end